ASMB Stock Analysis: Buy, Sell, or Hold?
ASMB - Assembly Biosciences, Inc
$29.01
-0.42 (-1.43%)
▼
5d:
+0.48%
30d:
-2.62%
90d:
-14.7%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When ASMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ASMB shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ASMB shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: ASMB is currently trading at $29.01, which is considered fair relative to its 30-day fair value range of $27.82 to $29.43.
Technical Outlook: Technically, ASMB is in a strong downtrend. Immediate support is located at $26.32, while resistance sits at $30.18.
Market Sentiment: ASMB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.75 (+64.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ASMB is in a strong downtrend. Immediate support is located at $26.32, while resistance sits at $30.18.
Market Sentiment: ASMB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.75 (+64.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$27.82 -
$29.43
Company Quality Score
61/100
(BUY)
Options IV Signal
22th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 22th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 64.6% below Wall St target ($47.75)
Fair Price Analysis
30-Day Fair Range
$27.82 -
$29.43
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$3.15
(10.9%)
Support & Resistance Levels
Support Level
$26.32
Resistance Level
$30.18
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-42.66
Wall Street Target
$47.75
(+64.6%)
Revenue Growth (YoY)
477.3%
Profit Margin
-8.5%
Share & Embed Analysis
Last updated: April 05, 2026 1:25 PM ET
Data refreshes hourly during market hours. Next update: 2:25 PM
Data refreshes hourly during market hours. Next update: 2:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
